

RESEARCH ARTICLE

Open Access

# Characterization of *Pf*TrxR inhibitors using antimalarial assays and *in silico* techniques

Ranjith Munigunti<sup>1†</sup>, Symon Gathiaka<sup>2†</sup>, Orlando Acevedo<sup>2</sup>, Rajnish Sahu<sup>3</sup>, Babu Tekwani<sup>3</sup> and Angela I Calderón<sup>1\*</sup>

## Abstract

**Background:** The compounds 1,4-naphthoquinone (1,4-NQ), bis-(2,4-dinitrophenyl)sulfide (2,4-DNPS), 4-nitrobenzothiadiazole (4-NBT), 3-dimethylaminopropiophenone (3-DAP) and menadione (MD) were tested for antimalarial activity against both chloroquine (CQ)-sensitive (D6) and chloroquine (CQ)-resistant (W2) strains of *Plasmodium falciparum* through an *in vitro* assay and also for analysis of non-covalent interactions with *P. falciparum* thioredoxin reductase (*Pf*TrxR) through *in silico* docking studies.

**Results:** The inhibitors of *Pf*TrxR namely, 1,4-NQ, 4-NBT and MD displayed significant antimalarial activity with IC<sub>50</sub> values of < 20 μM and toxicity against 3T3 cell line. 2,4-DNPS was only moderately active. *In silico* docking analysis of these compounds with *Pf*TrxR revealed that 2,4-DNPS, 4-NBT and MD interact non-covalently with the intersubunit region of the enzyme.

**Conclusions:** In this study, tools for the identification of *Pf*TrxR inhibitors using phenotypic screening and docking studies have been validated for their potential use for antimalarial drug discovery project.

**Keywords:** Malaria, *Plasmodium falciparum*, Thioredoxin reductase, Molecular modeling

## Background

Malaria, a tropical parasitic disease, continues to be the dominant cause of death in low-income countries especially in Africa and is considered to be one of the top three killers among communicable diseases [1]. Malaria caused by *Plasmodium falciparum* is considered to be the most deadly and also the one with highest rate of drug resistance [2]. Research investment in new and improved interventions will improve malaria cure, control, increase the cost-effectiveness of interventions and support efforts to eliminate malaria [3].

*P. falciparum* requires efficient antioxidant and redox systems to prevent damage caused by reactive oxygen species. In recent years, it has been shown that *P. falciparum* (*Pf*) possesses a functional low molecular weight thiol thioredoxin (Trx) system [4]. Thioredoxin reductase (TrxR) is an important enzyme of this redox system that helps the parasite to maintain an adequate intracellular redox environment during intraerythrocytic

development and proliferation. This antioxidant enzyme (*Pf*TrxR) is essential for the survival of *Plasmodium* parasites for combating intraerythrocytic oxidative stress. Disruption of this enzyme is a feasible way to interfere with intraerythrocytic development and proliferation of the malaria parasites [5]. The current chemotherapy for malaria as recommended by WHO focuses on artemisinin-based combination therapies (ACTs) as the front line of treatment for malaria disease. The main drawbacks of combination therapies are high cost, adverse drug reactions and a high degree of pharmacokinetic mismatch between components leading to prolonged exposure of parasites to low doses of partner drug and its active metabolites which may facilitate development of resistant parasites [6].

Development of parasites' resistance to the known antimalarials remains a major challenge for the effective management of malaria. Intensive drug discovery programs have aimed at developing new antimalarials or modifying current antimalarials to improve their efficacy and reduce evidence of resistance.

*In silico* molecular modeling methods, such as docking can aid in the drug discovery process by ascertaining the binding affinities of existing and hypothetical compounds

\* Correspondence: aic0001@auburn.edu

†Equal contributors

<sup>1</sup>Department of Pharmacal Sciences, 4306 Walker Building, Auburn University, Auburn, AL, USA

Full list of author information is available at the end of the article

towards *Pf*TrxR and the human isoform of this enzyme. Ideally, the simulations can also elucidate the origin behind the observed inhibition, as crystalline enzyme/inhibitor complexes of the thioredoxin protein for x-ray structure determination have not been reported. A comparison with other disulfide reductases including glutathione reductases reveals the most common inhibitor binding sites are at the active site and at the crystallographic 2-fold axis in the large cavity at the dimer interface. These sites can be exploited for structure-based inhibitor development. The dimer interface shows non-competitive or uncompetitive behavior and their interaction with the protein is purely non-covalent [7-10]. Docking calculations are well suited for exploration of this interface; however, the simulations are unable to reproduce covalent inhibitors that bind irreversibly at the active site. A combined experimental and computational effort may counterbalance this deficiency and provide an enhanced avenue for inhibitor development.

A comparison between the *h*TrxR and *Pf*TrxR structures shows that they have 46% sequence identity and overlay with an RMSD of 0.91 Å between the 374 monomer atom pairs. The most important difference that can be exploited for selective inhibition between the two enzymes is at the dimer interface. The interface in *Pf*TrxR is narrower than in *h*TrxR due to the presence of Tyr101 and His104 and can therefore host smaller molecules. Their counterparts in the human isoform are Gln72 and Leu75 and this difference can determine the chemical nature of suitable inhibitors [11]. The molecular surfaces of the parasite and the human enzymes also indicate that the charges on the cavity walls are different, with the *h*TrxR's being more negatively charged compared to the *Pf*TrxR's [11].

The current study is aimed to employ the combined approach of *in silico* molecular docking for identification of key interactions of *Pf*TrxR inhibitors to improve selectivity and phenotypic antimalarial assays for identification of activity against susceptible and drug-resistant *P. falciparum* blood stage cultures to assure the identification of specific *Pf*TrxR inhibitors as scaffolds for lead optimization.

## Results and discussion

The *in vitro* antimalarial activity of the five known inhibitors of *Pf*TrxR (1,4-NQ, 2,4-DNPS, 4-NBT, 3-DAP, MD) [12,13] (Figure 1; Table 1) was evaluated against both CQ-sensitive (D6 clone) and CQ resistant (W2 clone) strains of *P. falciparum*, while cell cytotoxicity was determined against 3T3 cells (Table 1) using the procedure described earlier. The compounds 1,4-NQ and 4-NBT were found to be the most active against the two strains of *P. falciparum*, MD and 2,4-DNPS were moderately active, and 3-DAP was inactive. In terms of antiplasmodial activity against the W2 strain, 1,4-NQ




Figure 1 The five *Pf*TrxR inhibitors.

and 4-NBT showed  $IC_{50}$  value of  $< 20 \mu M$ . The low correlation between the high *Pf*TrxR inhibitory activity and moderate antiplasmodial activity of 2,4-DNPS could be explained by an inability to penetrate the cell membranes. Accordingly, 2,4-DNPS is predicted to have poor Caco-2 and MDCK cell line permeability. Table 2 gives the computed octanol/water partition coefficient (logP), solubility in water (logS), polar surface area, and apparent Caco-2 and MDCK permeability for all compounds given in Figure 1, the enol form of 3-DAP, and CQ.

The lack of antiplasmodial activity of 3-DAP, a Mannich base, may be due to (i) non-specific alkylation of cellular thiol groups, and also (ii) due to the absence of active transport to red blood cells and parasites. The correlation between inhibition of *Pf*TrxR in the enzyme inhibition assays and antiplasmodial activity in cell culture allows for a better evaluation of biological activities of inhibitor compounds. The active compounds namely, 1,4-NQ, 2,4-DNPS, 4-NBT and MD showed more toxicity than 3-DAP against the 3T3 cell line. The 3T3 cells are epithelial cells that reflect toxicity against proliferating mammalian cells.

In order to test the five *Pf*TrxR inhibitors for their ability to induce signs of oxidative stress by accelerated generation and accumulation of reactive oxygen intermediates (superoxide radical, hydroxyl radical and hydrogen peroxide) [15] the intraerythrocytic formation of ROS was monitored in real-time for 120 min with 2'-7'-dichlorofluorescein diacetate (DCFDA), a fluorescent ROS probe [16]. Among the compounds tested 4-NBT, MD and 1,4-NQ caused a significant increase in oxidative stress (Figure 2). Whereas, 3-DAP and 2,4-DNPS did not cause the production of ROS. These results suggest that 4-NBT, MD and 1,4-NQ compromises the capability of erythrocytes to scavenge reactive oxygen intermediates. The accumulated intra-erythrocytic oxidative stress by these compounds may be responsible for the inhibition of *h*TrxR enzyme. The erythrocytes, our target cells, have higher capacity to produce oxidative stress than 3T3 cell line used for cytotoxicity assessment.

**Table 1 *Pf*TrxR inhibitory and antiplasmodial activities of tested compounds**

Test compounds	<i>Pf</i> TrxR IC <sub>50</sub> (μM)*	<i>Pf</i> (D6) CQ sensitive IC <sub>50</sub> (μM)**	SI D6	<i>Pf</i> (W2) CQ resistance IC <sub>50</sub> (μM)**	SI W2	3T3 IC <sub>50</sub> (μM)
1,4-NQ	0.75	8.9 ± 2.3	4.6	16.7 ± 3.7	2.4	38.5 ± 0.76
2,4-DNPS	0.5	91.2 ± 11.3	0.8	72.3 ± 11.3	1.0	79 ± 3.51
4-NBT	2	8.3 ± 2.1	10	9.8 ± 1.9	8	80 ± 1.15
3-DAP	15.4	>100	>1	>100	>1	>100
MD	1.6	18.5 ± 1.9	3.8	28.3 ± 5.6	2.5	70.5 ± 3.69
CQ		0.055 ± 0.006		0.440 ± 0.045		NC

\*IC<sub>50</sub> values, preparation of *Pf*TrxR and optimal experimental conditions for the *Pf*TrxR functional assay were reported in Andricopulo et al., 2006 [12]; Charvet et al., 2003 [13]; Munigunti et al., 2012 [14].

\*\*Values are mean ± S.D. of triplicate observations; SI: Selectivity index. NC: no cytotoxicity up to concentration much higher than the concentration responsible for its antiplasmodial activity.

The 1,4-NQ chemical features and the ability to generate 'OH suggest the proficiency in altering intracellular redox status [17]. The antimalarial naphthoquinones (1,4-NQ and MD) are believed to perturb the major redox equilibria of the targeted *P. falciparum* infected red blood cells, which might be removed by macrophages. This perturbation results in development arrest and death of the malaria parasite at the trophozoite stage [18].

Since these compounds were active against *Pf*TrxR as well, molecular docking was used to study their interactions with *Pf*TrxR to gain further insight into the mode of interaction for these molecules. MD [19], DNPS and 4-NBT [20] have been proposed to bind at the intersubunit region in *Pf*TrxR's. However, 1,4-NQ and 3-DAP bind to the reductase covalently precluding the use of docking calculations. For example, 1,4-NQ is an inhibitor of TrxR that behaves as a subversive substrate [19]. The compound 3-DAP inactivates TrxR by alkylating the C-terminal redox active catalytic Cys-Cys pair. This is achieved by the formation of a reactive α, β-unsaturated ketone intermediate after it undergoes deamination in solution [13]. Therefore 3-DAP acts an alkylator. The calculations predict the same activity trend observed in the experimental IC<sub>50</sub> values for the non-covalent inhibitors, 2,4-DNPS, MD, and 4-NBT in *Pf*TrxR (Table 3).


For the *Pf*TrxR/MD complex, pi stacking interactions are predicted to form between the inhibitor's phenyl ring

and Tyr101 side chain ring. The backbone nitrogen of Met105 is in close proximity to the carbonyl group of MD; however, the predicted angle between N-H and O of 85° impedes hydrogen bonding. The molecule further forms hydrophobic interactions with the phenyl ring of Tyr116' and the side chains of Ile108 from both subunits. Similar to MD, 4-NBT's phenyl ring also has pi-pi stacking with Tyr101's phenyl ring, but forms hydrophobic interactions only with Ile108 from subunit B in the large cavity. The nitro group causes the molecule to twist subtly compared to MD in order to better interact with the electrostatic surface created by the peptide bond between His104 and Met105's and sulfur (Figure 3). Compared to the size of the cavity, MD and 4-NBT are small molecules and do not fully interact with most of the residues lining the wall of the dimer interface.

2,4-DNPS forms the only electrostatic interaction at a distance of 3.9 Å with Asn481'. Pi stacking interactions are formed between one of the inhibitor's phenyl rings and Tyr101 side chain ring with the other phenyl ring of the molecule forming a parallel displaced pi stacking interaction with Tyr101' (subunit B). As with MD and 4-NBT, the side chains of Ile108 from both subunits form hydrophobic interactions with 2,4-DNPS. Most of the interactions the three molecules are forming with the proteins are with the intersecting helices between the two subunits of the enzymes. The experimental activities

**Table 2 Predicted physico-chemical properties of the compounds**

Molecule	log P octanol/water (M)	log S aqueous solubility (M)	Polar surface area (PSA)	Apparent caco-2 permeability (nm/sec)	Apparent MDCK permeability (nm/sec)
1,4 NQ	0.486	-0.764	57.199	954	470
2,4 DNPS	1.406	-3.444	177.135	5	2
4-NBT	0.746	-1.414	75.626	382	385
3-DAP	1.249	-0.313	32.353	819	441
3-DAP-enol	1.800	-1.170	25.296	842	454
MD	0.880	-1.312	55.456	1225	616
CQ	4.276	-3.585	24	1364	1862
Range 95% of drugs	(-2.0 / 6.5)	(-6.5 / 0.5)	(7.0 / 330.0)	(<25 poor, >500 great)	(<25 poor, >500 great)



**Figure 2** Formation of reactive oxygen species (ROS), as indicated by increase in fluorescence. DCFDA loaded human erythrocytes by five *PfTrxR* inhibitors.

for 2,4-DNPS and 4-NBT show selectivity between the parasite and human isoform of thioredoxin reductase (Table 4). The experimental values for 2,4-DNPS show an 8-fold selectivity for *PfTrxR*, whereas 4-NBT has a 25-fold selectivity. While the docking simulations correctly predicted binding trends, limitations in the method, including potentially inaccurate scoring functions, the use of rigid proteins, and a lack of solvation could have contributed to its inability to reproduce the large differences observed in the  $IC_{50}$  values.

The docked poses, however, have considerable differences within the cavity, which could point to the observed selectivity (Figure 4). The presence of Tyr101 in *PfTrxR* enables 2,4-DNPS to form a favorable pi stacking interaction with the phenyl ring of the molecule, whereas its counterpart in *hTrxR* is a Gln72 that orients the molecule to avoid steric clashes. This results in the second ring of the molecule forming a parallel displaced pi stacking interaction with Tyr101', whereas a hydrogen bond between the nitro group and Gln72' in the *hTrxR* is realized. The effect of this substitution on 4-NBT

seems to be the fact that the presence of Gln72 pushes the molecule deep into the large cavity precluding the interaction with the residues of the intersecting helices between the subunits. 1,4-NQ and 4-NBT can be considered to be attractive leads for further optimization as these compounds display good *PfTrxR* inhibitory and antiparasitic activity.

A thorough examination of the residues making any form of interaction with the small molecules showed that no other, including His104 (*PfTrxR*) and its counterpart in *hTrxR* (Leu75), influences the differences in binding between the parasite and human isoform. Figure 5 shows 2,4-DNPS docked in both proteins especially showing the positions of the His104 and Leu75 as an example.

## Conclusions

In this study, tools for the identification of *PfTrxR* inhibitors using phenotypic screening and docking studies have been validated for their potential use for antiparasitic drug discovery project.

## Experimental

### Chemicals and enzymes

Deionized water generated by a Milli-Q water system (Millipore, MA) was used in the experiments. All reagents were purchased from Sigma–Aldrich.


### Biological assays

#### Antimalarial assay

Briefly, antimalarial activity of the compounds were determined *in vitro* on chloroquine sensitive (D6, Sierra

**Table 3** Comparison between computed binding affinities at the dimer interface in *PfTrxR* and experimental  $IC_{50}$  values

Molecule	Computed binding affinity (kcal/mol)	Exptl. <i>PfTrxR</i> $IC_{50}$ ( $\mu$ M)
2,4-DNPS	-8.4	0.5
MD	-7.9	1.6
4-NBT	-6.0	2



**Table 4** Comparison between computed binding affinities at the dimer interface and experimental IC<sub>50</sub> values in *PfTrxR* and *hTrxR*

Molecule		<i>PfTrxR</i>	<i>hTrxR</i>
2,4-DNPS	Exptl. IC <sub>50</sub> ( $\mu$ M)	0.5	4
	Calc. binding affinity (kcal/mol)	-8.4	-8.1
4-NBT	Exptl. IC <sub>50</sub> ( $\mu$ M)	2	50
	Calc. binding affinity (kcal/mol)	-6.0	-5.7


Leone) and resistant (W2, IndoChina) strains of *P. falciparum*. The 96-well microplate assay is based on the effect of the compounds on growth of asynchronous cultures of *P. falciparum*, as determined by the fluorometric SYBR green assay [21].


#### Cytotoxicity assay

Cytotoxicity in terms of cell viability was evaluated using 3T3 cells by AlamarBlue assay [22]. This assay was conducted on compounds designated as active in the *PfTrxR* functional assay and the antimalarial phenotypic screening.

#### ROS assay

Accelerated generation and accumulation of reactive oxygen intermediates (superoxide radical, hydroxyl radical





and hydrogen peroxide) are mainly responsible for oxidative stress [15]. The intraerythrocytic formation of ROS was monitored in real-time with 2',7'-dichlorofluorescein diacetate (DCFDA), a fluorescent ROS probe [16]. Human erythrocytes collected in citrate phosphate anticoagulant were used. The erythrocytes were washed twice with 0.9% saline and suspended in PBSG at a hematocrit of 10%. A 60 mM stock of DCFDA was prepared in DMSO and added to the erythrocytes suspension in PBSG (10% hematocrit) to obtain the final concentration of 600  $\mu$ M. Erythrocytes suspension containing 600  $\mu$ M of DCFDA was incubated at 37°C for 20 min and centrifuged at 1000 *g* for 5 min. The pellet of DCFDA loaded erythrocytes was suspended in PBSG to 50% hematocrit and used for kinetic ROS formation assay. The assay was directly set up in a clear flat-bottom 96 well microplate. The reaction mixture contained 40  $\mu$ l of DCFDA loaded erythrocytes, the test compounds (50  $\mu$ M) and potassium phosphate buffer (100 mM, pH 7.4), to make up the final volume to 200  $\mu$ l. The controls without drug were also set up simultaneously. Each assay was set up at least in duplicate. The plate was immediately placed in a microplate reader programmed to kinetic measurement of fluorescence (excitation 488 nm and emission 535 nm) for 2 hours with 5 min time intervals.

## Computational studies

### Computational methods

AutoDock Vina [22] was used to dock inhibitors to the respective targets. Initial Cartesian coordinates for the protein-ligand structures were derived from reported crystal structures of *hTrxR* (PDB ID: 3QFA) [23] and *PfTrxR* (PDB ID: 4B1B) [11]. The protein targets were prepared for molecular docking simulation by removing water molecules and bound ligands. AutoDockTools (ADT) [24] was used to prepare the docking simulations

whereas Chimera was used to analyze the docking poses. All ligands were constructed using PyMol [25] with subsequent geometry optimizations carried out using the semi-empirical method PDDG/PM3 [20,26,27]. Polar hydrogens were added. ADME properties logP, logS, polar surface area, and apparent Caco-2 permeability for each ligand were computed using QikProp [28,29]. Conjugate gradient minimizations of the systems were performed using GROMACS [30]. A grid was centered on the catalytic active site region and included all amino acid residues within a box size set at  $x = y = z = 20$  Å.

### AutoDock Vina details

Standard flexible protocols of AutoDock Vina using the Iterated Local Search global optimizer [31] algorithm were used to evaluate the binding affinities of the molecules and interactions with the receptors. All ligands and docking site residues, as defined by the box size used for the receptors, were set to be rotatable. Calculations were carried out with the exhaustiveness of the global search set to 100, number of generated binding modes set to 20 and maximum energy difference between the best and the worst binding modes set to 5. Following completion of the docking search, the final compound pose was located by evaluation of AutoDock Vina's empirical scoring function where the conformation with the lowest docked energy value was chosen as the best.

### Competing interests

All the authors declare that they have no competing interests.

### Authors' contributions

AIC supervised all the research work. RM carried out the *PfTrxR* inhibitory assays and wrote the manuscript, which is part of his Ph.D. thesis. SG performed the docking experiments and helped writing the section. OA supervised the experiments and results of docking experiments. RS conducted the antimalarial and cytotoxicity assays. BT supervised the experiments and results of the antimalarial and cytotoxicity assays. All authors read and approved the manuscript.

### Acknowledgements

We are deeply indebted to Dr. Katja Becker from the Justus-Liebig University, Germany for supplying the enzyme *PfTrxR*. NCNPR is partially supported by USDA-ARS cooperative scientific agreement.

### Author details

<sup>1</sup>Department of Pharmacal Sciences, 4306 Walker Building, Auburn University, Auburn, AL, USA. <sup>2</sup>Department of Chemistry and Biochemistry, Auburn University, Auburn, AL, USA. <sup>3</sup>National Center for Natural Products Research & Department of Pharmacology, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, USA.

Received: 31 July 2013 Accepted: 5 November 2013

Published: 10 November 2013

### References

1. Becker K, Hu Y, Biller-Andorno N: Infectious diseases - a global challenge. *Int J Med Microbiol* 2006, **296**:179-185.
2. World Health Organization: *World malaria report 2012*; 2012. [http://www.who.int/malaria/publications/world\\_malaria\\_report\\_2012/report/en/](http://www.who.int/malaria/publications/world_malaria_report_2012/report/en/).
3. Roll Back Malaria: *The global malaria action plan: for a malaria-free world*. Geneva, Switzerland: Roll back Malaria Partnership; 2008.

4. Müller S: **Thioredoxin reductase and glutathione synthesis in *Plasmodium falciparum*.** *Redox Rep* 2003, **8**:251–255.
5. Müller S, Gilberger TW, Krnajski Z, Lüersen K, Meierjohann S, Walter RD: **Thioredoxin and glutathione system of malaria parasite *Plasmodium falciparum*.** *Protoplasma* 2001, **217**:43–49.
6. Nosten F, White NJ: **Artemisinin-based combination treatment of *falciparum* malaria.** *Am J Trop Med Hyg* 2007, **77**:181–192.
7. Savvides SN, Karplus PA: **Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor.** *J Biol Chem* 1996, **271**:8101–8107.
8. Karplus PA, Pai EF, Schulz GE: **Crystallographic study of the glutathione binding site of glutathione reductase at 0.3-nm resolution.** *Eur J Biochem* 1989, **178**:693–703.
9. Schönleben-Janias A, Kirsch P, Mittl PR, Schirmer RH, Krauth-Siegel RL: **Inhibition of human glutathione reductase by 10-aryloaloxazines: crystalline, kinetic, and electrochemical studies.** *J Med Chem* 1996, **39**:1549–1554.
10. Becker K, Christopherson RI, Cowden WB, Hunt NH, Schirmer RH: **Flavin analogs with antimalarial activity as glutathione reductase inhibitors.** *Biochem Pharmacol* 1990, **39**:59–65.
11. Boumis G, Giardina G, Angelucci F, Bellelli A, Brunori M, Dimastrogiovanni D, Saccoccia F, Miele AE: **Crystal structure of *Plasmodium falciparum* thioredoxin reductase, a validated drug target.** *Biochem Biophys Res Commun* 2012, **425**:806–811.
12. Andricopulo D, Akoachere MB, Krogh R, Nickel C, McLeish MJ, Kenyon GL, Arscott LD, Williams CH, Davioud-Charvet E, Becker K: **Specific inhibitors of *Plasmodium falciparum* thioredoxin reductase as potential antimalarial agents.** *Bioorg Medicinal Chem Lett* 2006, **16**:2283–2292.
13. Charvet ED, McLeish MJ, Veine DM, Giegel D, Arscott LD, Andricopulo AD, Becker K, Muller S, Schirmer RH, Williams CH, Kenyon GL: **Mechanism-based inactivation of thioredoxin reductase from *Plasmodium falciparum* by Mannich bases. implication for cytotoxicity.** *Biochemistry* 2003, **42**:13319–13333.
14. Munigunti R, Calderón AI: **Development of liquid chromatography/mass spectrometry based screening assay for PfTrxR inhibitors using relative quantitation of intact thioredoxin.** *Rapid Commun Mass Spectrom* 2012, **26**:1–6.
15. Sivilotti ML: **Oxidant stress and haemolysis of the human erythrocyte.** *Toxicol Rev* 2004, **23**:169–188.
16. Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL: **Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: Evaluation of eryptotic pathway.** *Toxicology* 2012, **294**:54–60.
17. Shang Y, Chen C, Li Y, Zhao J, Zhu T: **Hydroxyl radical generation mechanism during the redox cycling process of 1,4-naphthoquinone.** *Environ Sci Technol* 2012, **46**:2935–2942.
18. Müller T, Johann L, Jannack B, Brückner M, Lanfranchi DA, Bauer H, Sanchez C, Yardley V, Deregnauourt C, Schrével J, Lanzer M, Schirmer RH, Davioud-Charvet E: **Glutathione reductase-catalyzed cascade of redox reactions to bioactivate potent antimalarial 1,4-naphthoquinones - a new strategy to combat malarial parasites.** *J Am Chem Soc* 2011, **133**:11557–11571.
19. Morin T, Besset JC, Moutet M, Fayolle M, Bruckner M, Limosin D, Becker K, Davioud-Charvet E: **The aza-analogues of 1,4-naphthoquinones are potent substrates and inhibitors of plasmodial thioredoxin and glutathione reductases and of human erythrocyte glutathione reductase.** *Org Biomol Chem* 2008, **6**:2731–2742.
20. Tubert-Brohman I, Guimarães CRW, Jorgensen WL: **Extension of the PDDG/PM3 semiempirical molecular orbital method to sulfur, silicon, and phosphorus.** *J Chem Theory Comput* 2005, **1**:817–823.
21. Co E-M, Denuill RA, Reinbold DD, Waters NC, Johnson JD: **Assessment of malaria *in vitro* drug combination screening and mixed-strain infections using the malaria sybr green I-based fluorescence assay.** *Antimicrob Agents Chemother* 2009, **53**:2557–2563.
22. Hamalainen-Laanaya HK, Orloff MS: **Analysis of cell viability using time-dependent increase in fluorescence intensity.** *Anal Biochem* 2012, **429**:32–38.
23. Fritz-Wolf K, Kehr S, Stumpf M, Rahlfs S, Becker K: **Crystal structure of the human thioredoxin reductase-thioredoxin complex.** *Nat Commun* 2011, **2**:383.
24. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ: **AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility.** *J Comput Chem* 2009, **30**:2785–2791.
25. DeLano WL: *The PyMOL molecular graphics system*, Version 1.5.0.4: Schrödinger, LLC. San Carlos, CA, USA: DeLano Scientific; 2002.
26. Repasky MP, Chandrasekhar J, Jorgensen WL: **PDDG/PM3 and PDDG/MNDO: improved semiempirical methods.** *J Comput Chem* 2002, **23**:1601–1622.
27. Tubert-Brohman I, Guimarães CRW, Repasky MP, Jorgensen WL: **Extension of the PDDG/PM3 and PDDG/MNDO semiempirical molecular orbital methods to the halogens.** *J Comput Chem* 2003, **25**:138–150.
28. QikProp: *version 3.0*, Schrödinger. New York, NY: LLC; 2006.
29. Duffy EM, Jorgensen WL: **Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water.** *J Am Chem Soc* 2000, **122**:2878–2888.
30. Hess B, Kutzner C, Spoel D, Lindahl E: **GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation.** *J Chem Theory Comput* 2008, **4**:435–447.
31. Trott O, Olson AJ: **improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading.** *J Comput Chem* 2010, **31**:455–461.

doi:10.1186/1752-153X-7-175

**Cite this article as:** Munigunti et al.: Characterization of PfTrxR inhibitors using antimalarial assays and *in silico* techniques. *Chemistry Central Journal* 2013 **7**:175.

Publish with **ChemistryCentral** and every scientist can read your work free of charge

“Open access provides opportunities to our colleagues in other parts of the globe, by allowing anyone to view the content free of charge.”

W. Jeffery Hurst, The Hershey Company.

- available free of charge to the entire scientific community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright



Submit your manuscript here:  
<http://www.chemistrycentral.com/manuscript/>

**ChemistryCentral**